Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug targets 13 cancers in major trial

NCT ID NCT06330064

Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This study tests a drug called ifinatamab deruxtecan (I-DXd) in people with 13 types of advanced solid tumors that have come back or spread. The trial aims to see how well the drug shrinks tumors and what side effects it causes. About 520 participants will receive the drug intravenously, and the study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ifinatamab deruxtecan (I-DXd)
What this could lead to
If successful, this could provide a new treatment option for several advanced cancers that have stopped responding to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1B/2) with no control group, so results may not confirm benefit. Side effects from the drug could be significant, and not all tumor types may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 680 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Participants must meet all of the following criteria to be included in the study: Common Inclusion Criteria for All Participants 1. Participants must consent to provide a pretreatment tumor sample which has not been previously irradiated. Fresh biopsies are strongly preferred, however, if a fresh pretreatment biopsy is not feasible or the procedure is unsuccessful, an appropriate archival sample must be provided. The most recent archival sample obtained up to 5 years prior to consent is acceptable. 2. Participants ages ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is \>18 years). 3. At least 1 measurable lesion on computed tomography (CT) or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), as assessed by the investigator. 4. Documentation of radiological disease progression on or after the previous standard-of-care regimen. For NEC participants for which the standard therapy does not exist OR for which the standard therapy is not appropriate by the investigator: presence of advanced/metastatic disease without previous regimen is acceptable. 5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Additional Inclusion Criteria for EC Participants 1. Pathologically or cytologically documented EC of any histological carcinoma subtype or endometrial carcinosarcoma, irrespective of microsatellite instability or mismatch repair status. 2. Relapse or progression after a platinum-containing systemic treatment and an immune checkpoint inhibitor (ICI)-containing regimen (combined or sequential). Participants with actionable target tumor mutation should have been previously treated with targeted therapy, with a maximum of 3 prior lines of therapy for endometrial carcinoma or carcinosarcoma. Neoadjuvant/adjuvant therapy may count as 1 line of therapy if the subject progressed within 6 months after completion of therapy. Additional Inclusion Criteria for HNSCC Participants 1. Pathologically or cytologically documented unresectable or metastatic squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx, excluding nasopharynx, nasal cavity and paranasal sinuses, and unknown primary. 2. Has disease progression after platinum-based and ICI treatment, whether administered in combination or separately. Participants with actionable target tumor mutation should have been previously treated with targeted therapy, with a maximum of 2 prior therapy lines for unresectable or metastatic HNSCC. 3. Participants without radiographic evidence of major blood vessel invasion/infiltration or tumor demonstrating a greater than (\>)90-degree abutment or encasement of a major blood vessel. 4. Participants with no prior history of Grade greater than or equal to (≥)3 bleeding as per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 within 28 days prior to the start of study drug related to the current head and neck cancer may be included in the study. 5. Documented p16 status for oropharyngeal cancer (historical results are acceptable if available). Additional Inclusion Criterion for PDAC Participants 1\. Pathologically or cytologically documented unresectable or metastatic pancreatic adenocarcinoma that has relapsed or progressed after 1 prior line of gemcitabine-based systemic therapy in the locally advanced/metastatic setting or after 2 lines of therapy if the participant has actionable target tumor mutation and has been previously treated with targeted therapy. a. No prior treatment with topoisomerase I inhibitors, such as irinotecan or topotecan. Additional Inclusion Criteria for CRC Participants 1. Pathologically or cytologically documented unresectable or metastatic CRC with microsatellite stable status (MSS). 2. Relapse or progression after 1 prior line of systemic therapy including a fluoropyrimidine plus oxaliplatin with or without anti-vascular endothelial growth factor (VEGF) monoclonal antibody (mAb) or anti-epidermal growth factor receptor mAb therapy, as clinically indicated, or relapse or progression after 2 lines of therapy if the subject has received targeted therapy. Note: Prior adjuvant/neoadjuvant systemic cytotoxic chemotherapy will count as 1 line of prior systemic therapy if there is documented disease progression during therapy or within 6 months of chemotherapy completion. 3. No prior treatment with topoisomerase I inhibitors, such as irinotecan or topotecan. Additional Inclusion Criteria for HCC Participants 1. Pathologically or cytologically documented unresectable or metastatic HCC (fibrolamellar and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible) or noninvasive diagnosis of HCC as per the American Association for the Study of Liver Diseases (AASLD) criteria in participants with a confirmed diagnosis of cirrhosis. 2. Relapse or progression after 1 prior line of an ICI-containing regimen (combination or monotherapy) in the locally advanced/metastatic setting, or relapse or progression after 2 lines of therapy if the participant has an actionable target tumor mutation and has been treated with targeted therapy. 3. Barcelona Clinic Liver Cancer (BCLC) Stage B or C. 4. Liver function status should be Child-Pugh (CP) Class A. 5. Albumin-Bilirubin (ALBI) Grade 1 within 7 days prior to the first dose of study drug. 6. Participants with large esophageal varices at risk of bleeding must be treated with conventional medical intervention: beta blockers or endoscopic treatment. Additional Inclusion Criteria for Ad-eso/GEJ/Gastric Participants 1. Pathologically or cytologically documented unresectable or metastatic Ad-eso/GEJ/Gastric that has relapsed or progressed after 1 prior line of systemic therapy in the locally advanced/metastatic setting. a. Participants with PD-(L)1+ or MSI-H/dMMR should receive ICI treatment if ICIs are standard of care in the country, unless the participant is ineligible for ICI treatment. 2. If the participant has known history of HER2 positivity (defined by IHC 3+ or IHC 2+ and in situ hybridization \[ISH\] positive, as classified by American Society of Clinical Oncology - College of American Pathologists \[ASCO CAP\]) or actionable target, the participant must have been previously treated with a targeted therapy. Additional Inclusion Criteria for UC Participants 1. Pathologically or cytologically documented unresectable or metastatic UC of the bladder, renal pelvis, ureter, or urethra. Participants with histological variants are allowed if urothelial histology is predominant. Small cell/neuroendocrine tumors are not allowed even if mixed histology. 2. Relapse or progression after at least 1 prior line of ICI-containing systemic therapy, and 1 prior line of systemic chemotherapy, given in combination with other anticancer therapy or separately, with a maximum of 3 prior therapy lines. 1. At least 1 line of therapy should include enfortumab vedotin in countries where enfortumab vedotin is approved and available. 2. Perioperative systemic therapies will be counted as 1 line of therapy. 3. To meet inclusion criteria requirement of prior ICI-containing therapy, use in the perioperative or metastatic setting will suffice. 4. Participants with actionable target tumor mutation should have been previously treated with targeted therapy. 5. The same regimen administered twice in different disease settings will be counted as 1 line of prior therapy. Additional Inclusion Criteria for CC Participants 1. Histologically confirmed unresectable or metastatic CC that was previously treated with ≥1 prior line of systemic therapy in the locally advanced or metastatic setting. Participants with actionable target tumor mutation should have been previously treated with targeted therapy. 2. Participants should receive prior anti-programmed death 1 (PD-1)//programmed death-ligand 1 (PD-L1) treatment and/or tisotumab vedotin if those are standard of care in the country, unless the participant is ineligible for these treatments. Additional Inclusion Criteria for OVC Participants 1. Histologically confirmed high-grade serous OVC, high-grade endometrioid OVC, primary peritoneal cancer, or fallopian tube cancer that was previously treated with at least 1 line of platinum-based therapy and bevacizumab unless the participant is ineligible for treatment with bevacizumab. 2. Participant is no longer considered eligible for platinum-based therapy per the investigator's opinion or has progressed less than 180 days after the last dose of platinum therapy. 3. Participant is not considered primary platinum refractory and has not progressed during platinum treatment or within 4 weeks after the completion of platinum treatment. 4. Participants with actionable target tumor mutation should have been previously treated with targeted therapy. Additional Inclusion Criteria for BTC Participants 1. Pathologically or cytologically documented unresectable or metastatic BTC (intra- or extrahepatic cholangiocarcinoma or gallbladder carcinoma). 2. Relapse or progression after at least 1 prior line of systemic therapy, or 2 prior lines of systemic therapy if the participant has an actionable target and has received targeted therapy. 3. Histological subtypes other than ampullary cancer, small cell cancer, lymphoma, sarcoma, neuroendocrine tumors, mixed tumor histology, and/or mucinous cystic neoplasms (Please note that the histological subtypes listed here are not allowed.) Additional Inclusion Criteria for HER2-Low BC Participants 1. Pathologically or cytologically documented unresectable or metastatic BC. 2. Low HER2 expression, defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested), according to ASCO-CAP 2018 HER2 testing guidelines, based on most recent testing, regardless of hormonal status. 3. Progression on or after treatment with trastuzumab deruxtecan (T-DXd). 4. Relapse or progression after at least 2 and a maximum of 3 prior lines of systemic therapy. Participants with metastatic hormone receptor (HR)+ BC who have received endocrine-based therapy and have received at least 2 and a maximum of 3 prior lines of additional systemic therapy in the metastatic setting. Participants with actionable target tumor mutation should have been previously treated with targeted therapy. Additional Inclusion Criteria for HER2 IHC 0 BC Participants 1. Pathologically or cytologically documented unresectable or metastatic BC. 2. Negative for HER2 expression, defined as IHC 0 (ISH- or untested) according to ASCO-CAP 2018 HER2 testing guidelines, based on the most recent testing, regardless of hormonal status. 3. Relapse or progression after at least 2 and a maximum of 3 prior lines of systemic therapy. Participants with metastatic HR+ BC who have received endocrine-based therapy and have received at least 2 and a maximum of 3 prior lines of additional systemic therapy in the metastatic setting. Participants with actionable target tumor mutation should have been previously treated with targeted therapy. Additional Inclusion Criteria for Cutaneous (Acral and Non-acral) Melanoma Participants 1. Histologically or cytologically confirmed cutaneous (acral and non-acral) melanoma. 2. Disease progression while on or after having received treatment with ≥1 prior line of ICI based therapy. Prior anti-PD-(L)1 therapy in the adjuvant setting may be counted as 1 line if there is recurrence within 12 weeks of the last dose. If the subject had BRAF mutated melanoma or other actionable target tumor mutation, they must have had disease progression on targeted therapy as well. Additional Inclusion Criteria for NEC Participants 1. Histologically or cytologically confirmed NEC types other than neuroendocrine prostate cancer (NEPC), small cell lung cancer (SCLC), and Merkel Cell Carcinoma, as defined by WHO 2022. Participants must meet at least 1 of the following criteria: 1. Disease that is relapsed/refractory to standard systemic therapy OR 2. Disease for which standard therapy does not exist OR 3. Disease for which standard therapy is not considered appropriate by the investigator. 2. Participants with mixed histology of large-cell neuroendocrine carcinoma (LCNEC) and SCLC are eligible if the neuroendocrine component predominates and represents at least 50% of the overall tumor tissue. Exclusion Criteria: Participants who meet any of the following criteria will be disqualified from entering the study: 1. Prior treatment with orlotamab, enoblituzumab, or other B7-homologue 3 (B7-H3)-targeted agents, including I-DXd. 2. Prior discontinuation of an antibody drug conjugate (ADC) that consists of an exatecan derivative (e.g., T-DXd) due to treatment-related toxicities. 3. Clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis, defined as untreated or symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. 4. Inadequate treatment washout period before enrollment as specified in the protocol. 5. Any history of interstitial lung disease (ILD)/pneumonitis, current ILD, or suspicion of ILD.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Recurrent or metastatic solid tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus Biliary Tract Neoplasms colorectal neoplasm endometrium neoplasm hepatocellular carcinoma melanoma metastatic malignant neoplasm neuroendocrine carcinoma ovarian cancer Recurrence Squamous Cell Carcinoma of Head and Neck transitional cell carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Recurrent or metastatic solid tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    114 sites in 17 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Aichi Cancer Center Hospital

    RECRUITING

    Nagoya, Aichi-ken, 464-8681, Japan

  • Aidport Sp Z O.O.

    RECRUITING

    Skorzewo, 60-185, Poland

  • Amsterdam Umc, Locatie Vumc

    RECRUITING

    Amsterdam, 1081 HV, Netherlands

  • Ankara City Hospital

    RECRUITING

    Ankara, 06800, Turkey (Türkiye)

  • Ankara University Cebeci Hospital

    NOT_YET_RECRUITING

    Ankara, 6590, Turkey (Türkiye)

  • Azienda Socio Sanitaria Territoriale Niguarda (Grande Ospedale Metropolitano Niguarda)

    RECRUITING

    Milan, 20162, Italy

  • Biocenter

    RECRUITING

    Concepción, Biobio, 4030000, Chile

  • Blacktown Hospital

    RECRUITING

    Blacktown, New South Wales, NSW 2148, Australia

  • CRLCC Eugene Marquis

    RECRUITING

    Rennes, Ille Et Vilaine, 35042, France

  • Centre Georges François Leclerc

    RECRUITING

    Dijon, Cote dÝOr, 21000, France

  • Centre Léon Bérard

    RECRUITING

    Lyon, Rhone, 69008, France

  • Centro Del Cancer UC

    RECRUITING

    Santiago, Santiago Metropolitan, 8320000, Chile

  • Centro Hospitalar Universitario de Santo Antonio

    RECRUITING

    Porto, 4099-001, Portugal

  • Centro Hospitalar Universitário de Lisboa Norte

    RECRUITING

    Lisbon, 1649-035, Portugal

  • Centro Médico Austral

    ACTIVE_NOT_RECRUITING

    Ciudad Autonoma Buenos Aires, 1019, Argentina

  • Centro de Atenciăn E Investigaciăn Clănica En Oncologăa

    ACTIVE_NOT_RECRUITING

    Mérida, 97134, Mexico

  • Centro de Investigaciones Medicas Mar Del Plata

    RECRUITING

    Mar del Plata, Buenos Aires, B7600FYK, Argentina

  • Centro de Investigaciones Medicas y Desarrollo LC SRL LC Investigacion

    RECRUITING

    Ciudad Autonoma Buenos Aires, C1113AAE, Argentina

  • Centro de Pesquisas Clinicas da Fundação Doutor Amaral Carvalho

    RECRUITING

    Jaú, São Paulo, 17210-120, Brazil

  • Cepon - Centro de Pesquisas Oncolăgicas de Santa Catarina

    RECRUITING

    Florianópolis, Santa Catarina, 88034-000, Brazil

  • Charită - Campus Charită Mitte

    RECRUITING

    Berlin, 13353, Germany

  • China Medical University Hospital

    RECRUITING

    Taichung, 404327, Taiwan

  • Chu Besançon - Hôpital Jean Minjoz

    ACTIVE_NOT_RECRUITING

    Besançon, 25000, France

  • Chu de Liăge

    NOT_YET_RECRUITING

    Liège, 4000, Belgium

  • Clinica Redsalud Vitacura

    RECRUITING

    Santiago, Santiago Metropolitan, 8320000, Chile

  • Clinical Research Alliance, Inc

    RECRUITING

    Westbury, New York, 11590, United States

  • Cliniques Universitaires Saint-Luc

    RECRUITING

    Brussels, 1200, Belgium

  • Cork University Hospital

    NOT_YET_RECRUITING

    Cork, T12DC4A, Ireland

  • Cryptex Investigacion Clinica S.A. de C.V.

    ACTIVE_NOT_RECRUITING

    México, 06100, Mexico

  • DIABAID

    NOT_YET_RECRUITING

    Buenos Aires, C1061ABD, Argentina

  • Erasmus Medisch Centrum

    RECRUITING

    Rotterdam, 3015 GD, Netherlands

  • Erlanger Health, Inc

    RECRUITING

    Chattanooga, Tennessee, 37403, United States

  • Fondazione Del Piemonte Per L'Oncologia Irccs Candiolo

    RECRUITING

    Candiolo, 10060, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    RECRUITING

    Milan, 20133, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    RECRUITING

    Rome, 00168, Italy

  • Fundação Champalimaud

    RECRUITING

    Lisbon, 1400-038, Portugal

  • Gazi University Medical Faculty

    RECRUITING

    Ankara, 06560, Turkey (Türkiye)

  • Genesiscare North Shore Oncology

    RECRUITING

    St Leonards, New South Wales, 2065, Australia

  • Grand Hospital de Charleroi

    RECRUITING

    Charleroi, 6000, Belgium

  • Gulhane Training and Research Hospital

    RECRUITING

    Ankara, 06010, Turkey (Türkiye)

  • GustaveRoussy DptPharmacie

    RECRUITING

    Villejuif, Val De Marne, 94805, France

  • Hopital Saint Andre

    RECRUITING

    Bordeaux, Gironde, 33075, France

  • Hospital Aleman

    RECRUITING

    Buenos Aires, Ciudad Autonoma Buenos Aires, C1118AAT, Argentina

  • Hospital Clinic de Barcelona

    RECRUITING

    Barcelona, 08036, Spain

  • Hospital Clínico San Carlos

    RECRUITING

    Madrid, 28040, Spain

  • Hospital General Universitario Gregorio Marañon

    RECRUITING

    Madrid, 28009, Spain

  • Hospital Sirio Libanes

    RECRUITING

    Caba, Ciudad Autonoma Buenos Aires, C1419GEP, Argentina

  • Hospital São Lucas Da Pucrs

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90610-000, Brazil

  • Hospital Universitari Vall D'Hebron

    RECRUITING

    Barcelona, 08035, Spain

  • Hospital Universitario 12 de Octubre

    RECRUITING

    Madrid, 28041, Spain

  • Hospital Universitario La Paz

    RECRUITING

    Madrid, 28046, Spain

  • Hospital Universitario Virgen Macarena

    RECRUITING

    Seville, 41009, Spain

  • Hospital de Clínicas de Porto Alegre

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90035-903, Brazil

  • Hospital de Câncer de Barretos - Fundação Pio XII

    RECRUITING

    Barretos, São Paulo, 14784-400, Brazil

  • Huntsman Cancer Institute, University of Utah

    RECRUITING

    Salt Lake City, Utah, 84112, United States

  • ICO l'Hospitalet - Hospital Duran i Reynals

    RECRUITING

    Barcelona, 08908, Spain

  • Ic La Serena Research

    NOT_YET_RECRUITING

    La Serena, 1720430, Chile

  • Icahn School of Medicine At Mount Sinai Prime

    RECRUITING

    New York, New York, 10029, United States

  • Ico - Site René Gauducheau

    RECRUITING

    Saint-Herblain, Loire Atlantique, 44800, France

  • Inst Portude Onco do Porto

    RECRUITING

    Porto, 4200-072, Portugal

  • Institut Bergonié

    RECRUITING

    Bordeaux, Gironde, 33076, France

  • Institut Claudius Regaud

    NOT_YET_RECRUITING

    Toulouse, 31059, France

  • Institut Curie - Site de Paris

    RECRUITING

    Paris, Paris, 75005, France

  • Institut Régional Du Cancer de Montpellier

    RECRUITING

    Montpellier, Herault, 34298, France

  • Instituto Portuguăs de Oncologia de Lisboa Francisco Gentil, Epe

    RECRUITING

    Lisbon, 1099-023, Portugal

  • Instytut MSF Sp. z o.o.

    RECRUITING

    Lodz, 90-302, Poland

  • Istituto Clinico Humanitas

    RECRUITING

    Rozzano, 20089, Italy

  • Istituto Nazionale Tumori Fondazione G. Pascale

    RECRUITING

    Naples, 80131, Italy

  • Izmir Medicalpark Hospital

    NOT_YET_RECRUITING

    Izmir, 35530, Turkey (Türkiye)

  • James Lind Centro de Investigacion Del Cancer

    NOT_YET_RECRUITING

    Temuco, 4800827, Chile

  • Kindai University Hospital

    RECRUITING

    Ōsaka-sayama, Osaka, 589-8511, Japan

  • Koo Foundation Sun Yat-Sen cancer center

    RECRUITING

    Taipei, 11259, Taiwan

  • Los Angeles Cancer Network

    RECRUITING

    Los Angeles, California, 91204, United States

  • M Health Fairview University of Minnesota Medical Center

    RECRUITING

    Minneapolis, Minnesota, 55114, United States

  • MRUK-MED i Spółka z ograniczoną odpowiedzialnością

    RECRUITING

    Rzeszów, 35-021, Poland

  • Mater Misericordiae University Hospital

    RECRUITING

    Dublin, D07 R2WY, Ireland

  • Mazowiecki Szpital Wojewodzki W Siedlcach Sp Z O O

    RECRUITING

    Siedlce, 08-110, Poland

  • Medical Care & Research Sa de Cv

    ACTIVE_NOT_RECRUITING

    Mérida, 97070, Mexico

  • Medipol Mega University Hospital

    RECRUITING

    Bağcılar, Istanbul, 34214, Turkey (Türkiye)

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

  • National Cancer Center Hospital

    RECRUITING

    Chuo-ku, Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East

    RECRUITING

    Kashiwa, Chiba, 277-8577, Japan

  • National Cheng Kung University Hospitalx

    RECRUITING

    Tainan, 70403, Taiwan

  • National Hospital Organization Shikoku Cancer Center

    RECRUITING

    Matsuyama, Ehime, 791-0280, Japan

  • National Taiwan University Hospital

    RECRUITING

    Taipei, 10002, Taiwan

  • Orchard Healthcare Research Inc

    RECRUITING

    Skokie, Illinois, 60077, United States

  • Pih Health Hematology Medical Oncology

    RECRUITING

    Whittier, California, 90602, United States

  • Princess Alexandra Hospital

    RECRUITING

    Woolloongabba, Queensland, 4102, Australia

  • Radboudumc Nijmegen

    RECRUITING

    Nijmegen, 6525 GA, Netherlands

  • SCRI Oncology Partners

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • SPZOZ Szpital Uniwer w Krakowie

    RECRUITING

    Krakow, 30-688, Poland

  • Saitama Cancer Center

    RECRUITING

    Saitama, 362-0806, Japan

  • Shizuoka Cancer Center

    RECRUITING

    Nagaizumi-cho, Shizuoka, 411-8777, Japan

  • Slk-Kliniken Heilbronn Gmbh

    RECRUITING

    Heilbronn, Baden-Wurttemberg, 74078, Germany

  • St John of God Subiaco Hospital

    RECRUITING

    Subiaco, Western Australia, 6008, Australia

  • St Vincent'S Hospital Sydney

    RECRUITING

    Mount Kuring-Gai, New South Wales, 2080, Australia

  • St Vincent'S University Hospital

    RECRUITING

    Dublin, Dublin, D04 T6F4, Ireland

  • Staedtisches Klinikum Dresden Standort Dresden-Friedrichstadt

    RECRUITING

    Dresden, Saxony, 01067, Germany

  • Taipei Veterans General Hospital

    RECRUITING

    Taipei, 11217, Taiwan

  • Tallaght University Hospital

    RECRUITING

    Dublin, D24 NR0A, Ireland

  • Texas Oncology - West Texas

    RECRUITING

    Amarillo, Texas, 79124, United States

  • Texas Oncology Gulf Coast

    RECRUITING

    Pearland, Texas, 77584, United States

  • Texas Oncology, P.A.

    RECRUITING

    Dallas, Texas, 75246, United States

  • The Cancer Institute Hospital of Jfcr

    RECRUITING

    Koto-ku, Tokyo, 135-8550, Japan

  • The West Clinic

    RECRUITING

    Germantown, Tennessee, 38138, United States

  • Tri-Service General Hospital

    RECRUITING

    Taipei, 11490, Taiwan

  • Umc Utrecht

    RECRUITING

    Utrecht, 3584 CW, Netherlands

  • Univ der Johannes GutenbergU

    RECRUITING

    Mainz, Rhineland-Palatinate, 55131, Germany

  • Universitaetsklinikum Heidelberg

    RECRUITING

    Heidelberg, Baden-Wurttemberg, 69120, Germany

  • Universitair Medisch Centrum Groningen

    RECRUITING

    Groningen, 9713 GZ, Netherlands

  • Universitair Ziekenhuis Gent

    NOT_YET_RECRUITING

    Ghent, 9000, Belgium

  • University Hospital Galway

    NOT_YET_RECRUITING

    Galway, H91YR71, Ireland

  • Universitäres Krebszentrum Leipzig UCCL, UKL AöR

    RECRUITING

    Leipzig, Saxony, 04103, Germany

  • Universitätsklinikum Münster, Medizinische Klinik A

    RECRUITING

    Münster, North Rhine-Westphalia, 48149, Germany

  • Uz Leuven

    RECRUITING

    Leuven, 3000, Belgium

  • Valkyrie Clinical Trials

    ACTIVE_NOT_RECRUITING

    Los Angeles, California, 90067, United States

  • Virginia Cancer Specialists

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Vivantes Klinikum Neukoelln

    RECRUITING

    Berlin, 12351, Germany

  • Wenatchee Valley Hospital and Clinics

    RECRUITING

    Wenatchee, Washington, 98801, United States

  • White Plains Hospital

    RECRUITING

    White Plains, New York, 10601, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.